Exagen inc. partners with boston's tufts medical center to offer avise® testing as an in-network benefit for patients suffering from debilitating autoimmune diseases

San diego, jan. 21, 2021 (globe newswire) -- exagen inc. (nasdaq: xgn), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all avise test offerings (ctd, lupus, sle prognostic, sle monitor, aps, vasculitis aav, mtx, and hcq) are now a contracted in-network service with tufts medical center, an internationally-respected academic medical center.
XGN Ratings Summary
XGN Quant Ranking